Insider Transaction: Cytokinetics CEO Robert Blum Sells 7,500 Shares for $575,700
Robert I. Blum, President & CEO of Cytokinetics (NASDAQ:CYTK), reported the sale of 7,500 shares on Aug. 10, 2026, as disclosed in a recent SEC Form 4 filing. Transaction summary Transaction value based on SEC Form 4 weighted average sale price ($76.76); post-transaction value based on Aug. 10, 2026, market close ($77.49). Key questions What…
